Maze Therapeutics, a US-based precision medicines developer co-founded by researchers from Harvard University, Stanford University and University of California, San Francisco, procured $190m in funding led by Matrix Capital Management yesterday.

General Catalyst, Andreesen Horowitz’s Bio+Health, Woodline Partners, Casdin Capital, City Hill Ventures, Foresite Capital, Driehaus Capital Management, Moore Strategic Ventures, Terra Magnum Capital Partners, NS Investments and unnamed others took part in the round.

Maze Therapeutics is working on treatments for genetically defined diseases with a high unmet need,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email Linked in